ATE159856T1 - Verwendung von fettsäuren zur erhöhung der calciumabsorption im darm - Google Patents
Verwendung von fettsäuren zur erhöhung der calciumabsorption im darmInfo
- Publication number
- ATE159856T1 ATE159856T1 AT93306444T AT93306444T ATE159856T1 AT E159856 T1 ATE159856 T1 AT E159856T1 AT 93306444 T AT93306444 T AT 93306444T AT 93306444 T AT93306444 T AT 93306444T AT E159856 T1 ATE159856 T1 AT E159856T1
- Authority
- AT
- Austria
- Prior art keywords
- calcium absorption
- intestinal
- fatty acids
- increase calcium
- increase
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 title abstract 2
- 239000011575 calcium Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fertilizers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929217780A GB9217780D0 (en) | 1992-08-21 | 1992-08-21 | Fatty acid treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE159856T1 true ATE159856T1 (de) | 1997-11-15 |
Family
ID=10720716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93306444T ATE159856T1 (de) | 1992-08-21 | 1993-08-16 | Verwendung von fettsäuren zur erhöhung der calciumabsorption im darm |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5618558A (enExample) |
| EP (1) | EP0585026B1 (enExample) |
| JP (1) | JPH06157303A (enExample) |
| KR (1) | KR940003553A (enExample) |
| CN (1) | CN1049334C (enExample) |
| AT (1) | ATE159856T1 (enExample) |
| AU (1) | AU666747B2 (enExample) |
| CA (1) | CA2104567A1 (enExample) |
| DE (1) | DE69315020T2 (enExample) |
| DK (1) | DK0585026T3 (enExample) |
| ES (1) | ES2110060T3 (enExample) |
| GB (1) | GB9217780D0 (enExample) |
| GR (1) | GR3025898T3 (enExample) |
| HK (1) | HK1000997A1 (enExample) |
| MY (1) | MY109928A (enExample) |
| NO (1) | NO306655B1 (enExample) |
| NZ (1) | NZ248422A (enExample) |
| RU (1) | RU2122409C1 (enExample) |
| SG (1) | SG80536A1 (enExample) |
| TW (1) | TW323230B (enExample) |
| ZA (1) | ZA935976B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9325445D0 (en) | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
| GB9403855D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| EP0711503A3 (en) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
| US5804210A (en) * | 1996-08-07 | 1998-09-08 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein |
| GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
| AU8857298A (en) * | 1997-07-16 | 1999-02-10 | Societe Des Produits Nestle S.A. | Method for prophylaxis or treatment of bone density loss |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US6479545B1 (en) * | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
| EG22407A (en) | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
| EP1852115A1 (en) * | 2001-03-15 | 2007-11-07 | DSM IP Assets B.V. | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| CN1259044C (zh) * | 2001-03-30 | 2006-06-14 | 日清奥利友集团株式会社 | 骨代谢改善剂 |
| US7098352B2 (en) * | 2001-11-16 | 2006-08-29 | Virtus Nutrition Llc | Calcium salt saponification of polyunsaturated oils |
| EP1711173A2 (en) * | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| EA200602014A1 (ru) * | 2004-04-30 | 2007-08-31 | ВИРТУС НЬЮТРИШН ЭлЭлСи | Синтез солей одновалентных и двухвалентных металлов полиненасыщенных жирных кислот |
| EP1968402A2 (en) * | 2005-10-07 | 2008-09-17 | Ocean Nutrition Canada Limited | Salts of fatty acids and methods of making and using thereof |
| DE102007022694A1 (de) * | 2007-05-11 | 2008-11-13 | Humana Milchunion Eg | Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme |
| DE102007039310A1 (de) * | 2007-08-13 | 2009-02-19 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| AU2009288066B2 (en) | 2008-09-02 | 2015-12-24 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| PT3037089T (pt) | 2009-02-10 | 2020-03-04 | Amarin Pharmaceuticals Ie Ltd | Ester etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia |
| NZ807894A (en) | 2009-04-29 | 2025-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| DK3278665T3 (da) | 2009-04-29 | 2020-11-30 | Amarin Pharmaceuticals Ie Ltd | Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA3129996C (en) | 2009-06-15 | 2025-09-02 | Amarin Pharmaceuticals Ireland Limited | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| BR112012022336A2 (pt) * | 2010-03-04 | 2020-07-21 | Amarin Pharma, Inc. | composições e seus usos para tratar e/ou prevenir doença cardiovascular |
| US8178707B2 (en) | 2010-03-25 | 2012-05-15 | Jost Chemical Company | Co-precipitated salts of fatty acids |
| CN101978949A (zh) * | 2010-11-16 | 2011-02-23 | 王京南 | γ-亚麻酸酯脂肪乳静脉注射液及其制造方法 |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US8728546B1 (en) | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| MX375328B (es) | 2014-06-04 | 2025-03-06 | Ds Biopharma Ltd | Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| BR112018073060A2 (pt) * | 2016-06-01 | 2019-04-09 | Nestec S.A. | composição para uso na profilaxia de doença alérgica |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| WO2021097120A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1417119A (en) * | 1972-11-30 | 1975-12-10 | Thiele G H | Process for treating bones |
| GB8621816D0 (en) * | 1986-09-10 | 1986-10-15 | Efamol Ltd | Therapeutic composition |
| JPH0625057B2 (ja) * | 1987-12-14 | 1994-04-06 | 日本油脂株式会社 | 骨形成促進剤 |
| GB9112052D0 (en) * | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
-
1992
- 1992-08-21 GB GB929217780A patent/GB9217780D0/en active Pending
-
1993
- 1993-08-16 AU AU44666/93A patent/AU666747B2/en not_active Ceased
- 1993-08-16 DE DE69315020T patent/DE69315020T2/de not_active Expired - Fee Related
- 1993-08-16 ZA ZA935976A patent/ZA935976B/xx unknown
- 1993-08-16 US US08/106,989 patent/US5618558A/en not_active Expired - Fee Related
- 1993-08-16 EP EP93306444A patent/EP0585026B1/en not_active Expired - Lifetime
- 1993-08-16 JP JP5202396A patent/JPH06157303A/ja active Pending
- 1993-08-16 ES ES93306444T patent/ES2110060T3/es not_active Expired - Lifetime
- 1993-08-16 DK DK93306444.6T patent/DK0585026T3/da active
- 1993-08-16 AT AT93306444T patent/ATE159856T1/de not_active IP Right Cessation
- 1993-08-16 SG SG9605801A patent/SG80536A1/en unknown
- 1993-08-17 NZ NZ248422A patent/NZ248422A/en unknown
- 1993-08-20 RU RU93049153A patent/RU2122409C1/ru active
- 1993-08-20 NO NO932983A patent/NO306655B1/no not_active IP Right Cessation
- 1993-08-20 CA CA002104567A patent/CA2104567A1/en not_active Abandoned
- 1993-08-20 KR KR1019930016204A patent/KR940003553A/ko not_active Ceased
- 1993-08-21 CN CN93118320A patent/CN1049334C/zh not_active Expired - Fee Related
- 1993-08-21 MY MYPI93001672A patent/MY109928A/en unknown
- 1993-08-23 TW TW082106797A patent/TW323230B/zh active
-
1997
- 1997-12-29 HK HK97102670A patent/HK1000997A1/en not_active IP Right Cessation
-
1998
- 1998-01-14 GR GR980400071T patent/GR3025898T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY109928A (en) | 1997-09-30 |
| DE69315020T2 (de) | 1998-04-16 |
| GR3025898T3 (en) | 1998-04-30 |
| CA2104567A1 (en) | 1994-02-22 |
| NO306655B1 (no) | 1999-12-06 |
| NZ248422A (en) | 1997-06-24 |
| ZA935976B (en) | 1994-03-14 |
| US5618558A (en) | 1997-04-08 |
| KR940003553A (ko) | 1994-03-12 |
| CN1049334C (zh) | 2000-02-16 |
| CN1091285A (zh) | 1994-08-31 |
| EP0585026A1 (en) | 1994-03-02 |
| GB9217780D0 (en) | 1992-10-07 |
| DK0585026T3 (da) | 1998-06-02 |
| SG80536A1 (en) | 2001-05-22 |
| NO932983D0 (no) | 1993-08-20 |
| ES2110060T3 (es) | 1998-02-01 |
| HK1000997A1 (en) | 1998-05-15 |
| AU666747B2 (en) | 1996-02-22 |
| TW323230B (enExample) | 1997-12-21 |
| AU4466693A (en) | 1994-02-24 |
| NO932983L (no) | 1994-02-22 |
| DE69315020D1 (de) | 1997-12-11 |
| EP0585026B1 (en) | 1997-11-05 |
| JPH06157303A (ja) | 1994-06-03 |
| RU2122409C1 (ru) | 1998-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE159856T1 (de) | Verwendung von fettsäuren zur erhöhung der calciumabsorption im darm | |
| RU93049153A (ru) | Лечение жирными кислотами | |
| ATE96313T1 (de) | Fettsaeure-zusammensetzungen. | |
| PT956013E (pt) | Preparacao farmaceutica compreendendo acido eicosapentaenoico e/ou acido estearidonico | |
| ES2107622T3 (es) | Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal. | |
| ES2045120T3 (es) | Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria. | |
| ES2053856T3 (es) | Derivados del acido 4-quinoleino carboxilico utiles para el tratamiento de enfermedades de la piel y del muco-epitelio. | |
| ATE164518T1 (de) | Verwendung von fettsäuren zur behandlung von abnormalen verkalkung des gewebes | |
| ATE63684T1 (de) | Deodorant. | |
| FI944656A0 (fi) | Uudet kardioprotektiivset aineet | |
| ES2011472B3 (es) | Procedimiento para el tratamiento de soluciones acuosas producidas en la carboxilacion de compuestos olefinicos no saturados. | |
| FR2716891B1 (fr) | Produits colloïdaux contenant du calcium, du baryum et/ou du magnésium ainsi que du bismuth, modifiés par action d'acides carboxyliques contenant du soufre et éventuellement de l'azote. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |